GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Revenue
中文

Acrux (ASX:ACR) Revenue : A$11.42 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Acrux Revenue?

Acrux's revenue for the six months ended in Dec. 2023 was A$4.41 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$11.42 Mil. Acrux's Revenue per Share for the six months ended in Dec. 2023 was A$0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.04.

During the past 12 months, the average Revenue per Share Growth Rate of Acrux was 333.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 60.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -31.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Acrux's highest 3-Year average Revenue per Share Growth Rate was 165.20% per year. The lowest was -71.20% per year. And the median was 5.65% per year.


Acrux Revenue Historical Data

The historical data trend for Acrux's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Revenue Chart

Acrux Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 1.25 1.34 1.72 8.43

Acrux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 1.02 1.42 7.01 4.41

Competitive Comparison of Acrux's Revenue

For the Biotechnology subindustry, Acrux's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acrux's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's Revenue distribution charts can be found below:

* The bar in red indicates where Acrux's Revenue falls into.



Acrux Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$11.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acrux  (ASX:ACR) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Acrux Revenue Related Terms

Thank you for viewing the detailed overview of Acrux's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Acrux (ASX:ACR) Business Description

Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.